Private equity firm Sycamore Partners is reportedly considering selling UK pharmacy and beauty chain Boots for US$10 billion, just one year after acquiring it through the US$23.7 billion takeover of Walgreens Boots Alliance (WBA). This potential sale could sideline earlier IPO plans and signals a fast-track monetization strategy, offering overseas medical aesthetics buyers and distributors a glimpse into shifting ownership dynamics in the beauty retail supply chain.
Deal structure and rationale
Sycamore originally took control of Boots in 2025 when it acquired WBA. After breaking WBA into five separate operating businesses, Boots now functions as a standalone asset that can be sold for a premium. The firm focuses on restructuring, improving operations, and monetizing assets for a fast return, rather than holding assets indefinitely. Selling to a private bidder offers speed, confidentiality, and a guaranteed price tag, backed by Boots' financial performance.
Potential bidders and market interest
The Canadian arm of the Weston Family, which owns the Shoppers Drug Mart pharmacy chain, has shown interest. Operating through their holding company Wittington Investments, the Weston Family acquired Shoppers Drug Mart for C$12.4 billion (US$8.90 billion) in 2013, and it now operates over 1,300 stores across Canada. Buying Boots would award them an established retail footprint in the UK, marking their return after selling Selfridges for £4 billion (US$5.35 billion) in 2022. Australia's Sigma Healthcare, a pharmaceutical wholesaler and retailer, has also acknowledged preliminary discussions.
Boots' financial and operational performance
Boots reported a 3.2% rise in revenue to £7.5 billion (US$10 billion) for fiscal 2025, alongside a pre-tax profit jump of 25% to £337 million (US$450.75 million). Last year, Boots added 61 brands to its offerings, including Fenty Beauty and MAC. The retailer says the modernized beauty division helped boost results. Additionally, Alex Baldock, CEO at Currys, was appointed as Boots' new CEO, replacing Ornella Barra who is stepping down to become chair.
Regulatory and channel signals
A potential sale could oust plans to launch Boots on the London Stock Exchange, which industry reporting notes would have taken years, required extensive regulatory disclosure, and exposed Boots to stock market volatility. The move comes as many beauty industry behemoths weigh their business options. In March, Unilever announced it would divest its entire Food business to focus on Home & Personal Care. International Flavors and Fragrances (IFF) also secured a US$4.3 billion deal to sell its Food Ingredients business to double down on scent and health.
Sourcing context
For overseas medical aesthetics buyers and distributors, the potential Boots sale signals a broader industry trend of portfolio simplification and focus on higher-growth segments. Boots' strengthened beauty division, with added brands like Fenty Beauty and MAC, underscores the importance of premium beauty retail in the supply chain. Any change in ownership could affect distribution channels, brand partnerships, and market access for aesthetic product suppliers.
Source: Read the original report | Published: June 11, 2026